Cidara Historical Income Statement
| CDTX Stock | USD 20.20 0.61 3.11% |
Historical analysis of Cidara Therapeutics income statement accounts such as Selling General Administrative of 14 M, Other Operating Expenses of 63.2 M or Research Development of 49 M can show how well Cidara Therapeutics performed in making a profits. Evaluating Cidara Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cidara Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Cidara Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cidara Therapeutics is a good buy for the upcoming year.
Cidara |
About Cidara Income Statement Analysis
Cidara Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cidara Therapeutics shareholders. The income statement also shows Cidara investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Cidara Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cidara Therapeutics. It is also known as Cidara Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Cidara Therapeutics minus its cost of goods sold. It is profit before Cidara Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from Cidara Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cidara Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cidara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.At this time, Cidara Therapeutics' Total Other Income Expense Net is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 204 K in 2024, whereas Interest Expense is likely to drop slightly above 210.4 K in 2024.
Cidara Therapeutics income statement Correlations
Click cells to compare fundamentals
Cidara Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cidara Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 221K | 262K | 212K | 191K | 219.7K | 210.4K | |
| Selling General Administrative | 16.2M | 15.9M | 18.7M | 18.5M | 18.3M | 14.0M | |
| Other Operating Expenses | 62.6M | 83.9M | 91.8M | 94.0M | 88.4M | 63.2M | |
| Operating Income | (41.7M) | (71.8M) | (42.3M) | (29.7M) | (24.5M) | (25.7M) | |
| Ebit | (41.7M) | (71.8M) | (42.3M) | (29.7M) | (24.5M) | (25.7M) | |
| Research Development | 46.4M | 68.0M | 73.1M | 75.5M | 68.5M | 49.0M | |
| Ebitda | (42.1M) | (71.6M) | (43.5M) | (28.5M) | (24.4M) | (25.6M) | |
| Total Operating Expenses | 62.6M | 83.9M | 91.8M | 94.0M | 86.9M | 63.0M | |
| Income Before Tax | (41.1M) | (72.1M) | (42.5M) | (29.5M) | (22.5M) | (23.6M) | |
| Total Other Income Expense Net | 632K | (262K) | (212K) | 191K | 2.0M | 2.1M | |
| Net Income | (40.1M) | (72.4M) | (43.9M) | (29.8M) | (22.9M) | (24.1M) | |
| Depreciation And Amortization | (411K) | 286K | (1.2M) | 1.2M | 118K | 204K | |
| Total Revenue | 20.9M | 12.1M | 49.6M | 64.3M | 63.9M | 67.1M | |
| Gross Profit | (25.5M) | (56.0M) | 49.6M | 64.3M | 62.4M | 65.5M | |
| Net Income From Continuing Ops | (41.1M) | (72.1M) | (42.5M) | (29.8M) | (22.9M) | (24.1M) | |
| Cost Of Revenue | 46.4M | 68.0M | 189K | 143K | 1.5M | 1.4M | |
| Net Income Applicable To Common Shares | (41.1M) | (74.9M) | (42.5M) | (29.8M) | (26.8M) | (28.2M) | |
| Income Tax Expense | (1.0M) | 262K | 1.4M | 272K | 443K | 606.8K | |
| Net Interest Income | 221K | (262K) | (212K) | 191K | 2.0M | 2.1M | |
| Non Operating Income Net Other | 4.3M | 632K | (262K) | 191K | 171.9K | 163.3K | |
| Reconciled Depreciation | 328K | 286K | (1.2M) | 1.2M | 118K | 219.1K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.